共 80 条
[1]
Signs V(2013)Carbapenem-Reistant Enterobacteriaceae MMWR 62 165-170
[2]
Vardakas KZ(2012)Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis J Antimicrob Chemother 67 2793-2803
[3]
Tansarli GS(2002)The Cost of Antibiotic Resistance: Effect of Resistance Among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on Length of Hospital Stay Infection Control and Hospital Epideimology 23 106-108
[4]
Rafailidis PI(2007)Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis J Antimicrob Chemother 60 913-920
[5]
Falagas ME(2014)Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort Infection 42 991-997
[6]
Schwaber MJ(2003)Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum B-Lactamase Clin Infect Dis 39 31-37
[7]
Carmeli Y(2012)Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship Infect Control Hosp Epidemiol 33 817-830
[8]
Leistner R(2010)Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy Antimicrob Agents Chemother 54 4085-4091
[9]
Gurntke S(2009)Extended-spectrum beta-lactamase-producing organisms J Hosp Infect 73 345-354
[10]
Sakellariou C(2005)Extended-spectrum beta-lactamases: a clinical update Clin Microbiol Rev 18 657-686